There is a crisis in medical imaging. Current MRI contrast agents (GBCAs) contain toxic gadolinium. GBCAs cause brain deposition of gadolinium in all patients, and pose devastating risks to renally impaired patients. Each year over 4 million very sick patients worldwide must be denied crucial diagnostic imaging, and over 30 million patients are put at risk.
Reveal solves this >$1B problem with a biocompatible gadolinium-free contrast agent that is a safe, direct substitute for GBCAs.

2017 Boston Gold Winner
Sub industry